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Abstract
!
The aggregation of the microtubule-associated
protein tau is a significant event in many neuro-
degenerative diseases including Alzheimerʼs dis-
ease. The inhibition or reversal of tau aggregation
is therefore a potential therapeutic strategy for
these diseases. Fungal natural products have
proven to be a rich source of useful compounds
having wide varieties of biological activity. We
have screened Aspergillus nidulans secondary me-
tabolites containing aromatic ring structures for
their ability to inhibit tau aggregation in vitro us-
ing an arachidonic acid polymerization protocol
and the previously identified aggregation inhib-
itor emodin as a positive control. While several
compounds showed some activity, 2,ω-dihy-
droxyemodin, asperthecin, and asperbenzalde-
hyde were potent aggregation inhibitors as deter-
mined by both a filter trap assay and electron mi-
croscopy. In this study, these three compounds
were stronger inhibitors than emodin, which has
been shown in a prior study to inhibit the heparin
induction of tau aggregation with an IC50 of 1–
5 µM. Additionally, 2,ω-dihydroxyemodin, asper-
thecin, and asperbenzaldehyde reduced, but did
not block, tau stabilization of microtubules. 2,ω-
Dihydroxyemodin and asperthecin have similar
structures to previously identified tau aggrega-
tion inhibitors, while asperbenzaldehyde repre-
sents a new class of compounds with tau aggrega-
tion inhibitor activity. Asperbenzaldehyde can be
readily modified into compounds with strong li-
poxygenase inhibitor activity, suggesting that
compounds derived from asperbenzaldehyde
could have dual activity. Together, our data dem-
onstrates the potential of 2,ω-dihydroxyemodin,
asperthecin, and asperbenzaldehyde as lead com-
pounds for further development as therapeutics
to inhibit tau aggregation in Alzheimerʼs disease
and neurodegenerative tauopathies.
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Alzheimerʼs disease and other neurodegenerative
tauopathies are characterized by the abnormal
accumulation of aggregated forms of the microtu-
bule associated protein tau. Tau aggregation cor-
relates with the type and severity of cognitive im-
pairment in Alzheimerʼs disease [1]; mutations in
the tau gene can lead to neurodegeneration [2,3],
and tau aggregation can lead to cell death and
cognitive defects in cellular and animal models
(reviewed in [4]). It is therefore believed that in-
hibiting tau aggregation is a viable therapeutic
target for the treatment of Alzheimerʼs disease
and related tauopathies [5,6].
Tau aggregation is caused when natively unfolded
sequences in their microtubule-binding repeats 3Paranjaand 4 undergo a conformational change, poten-
tially as a result of phosphorylation [7–9], to β-
sheet structure [10,11] and then interact with
one another to form amyloid-type filaments. It is
believed that small molecules that interact with
the β-sheet structure inhibit tau aggregation by
preventing the addition of tau molecules to the
growing aggregate. Tau aggregation inhibitors
identified to date belong to chemical classes in-
cluding phenothiazines [12,13], cyanine dyes
[14,15], polyphenols [12], pthalocyanines [12],
anthraquinones [16], N-phenylamines [17], phe-
nylthiazolyl-hydrazides [18], rhodanines [19],
quinoxalines [20], and thienopyridazines [21].
These compounds represent a wide variety of
chemical structures, but they share the common
feature of multiple aromatic rings. While it is notpe SR et al. Inhibition of Tau… Planta Med 2014; 80: 77–85
Fig. 1 Compounds used in this study. The chemi-
cal structures are drawn for the 17 compounds
used. The names of the compounds are included
with their structure along with a compound num-
ber. Each compound was purified from a single
HPLC peak. The purity of each compound was esti-
mated from its 1H NMR spectrum (see Supporting
Information) and is listed in Table 1S. In F9775 B,
NOESY correlations between H-13/H3-7 and H-13/
OH-8 suggested that H3-7, OH-8, and H-13 are on
the same face. The fact that the specific rotation of
F9775 A and B is close to zero indicated that both
compounds are racemic mixtures [48]. Stereocen-
ters on the side chain of 3′-hydroxyversiconol have
































































l.known whether these inhibitors will be effective in vivo or
whether they have suitable bioavailability or pharmacokinetic
properties to serve this purpose, it is important to have lead com-
pounds with the appropriate biological activity for further devel-
opment.
Fungal natural products and secondary metabolites have histori-
cally been a rich source of compounds with useful biological ac-
tivities such as antibiotics, antimicrobials, and antioxidants. Re-
cent advances in genetics and genomics have greatly facilitated
the study of fungal metabolic pathways along with the identifica-
tion and purification of biologically interesting compounds. Us-
ing an efficient gene targeting system [22–24], we have identified
several biosynthetic pathways in Aspergillus nidulans (Trichoco-
maceae) that lead to a wide variety of chemical structures [25–
34]. Many of these compounds contain aromatic ring structures
common to previously identified tau aggregation inhibitors. We
therefore sought to determine whether A. nidulans secondary
metabolites may also have tau aggregation inhibition activity.
We assessed the biological activity of 17 compounds using a stan-
dard arachidonic acid induction of tau aggregation in vitro [35]
followed by a filter trap assay [16,36] and electron microscopy
[37,38]. The previously identified tau aggregation inhibitor emo-
din served as a positive control. Several of the compounds inhib-
ited aggregation, and the inhibition by three of the compounds
was reproducible and dose-dependent. We also assessed the ef-
fect of the compounds on tauʼs normal function of stabilizing mi-
crotubules using a fluorescence-based assay [39]. While the com-
pounds reduced the activity of tau in a concentration-dependentParanjape SR et al. Inhibition of Tau… Planta Med 2014; 80: 77–85manner, tau retained its ability to stimulate the polymerization of
microtubules in the presence of the compounds, making them in-
teresting candidate compounds for further development. Lastly,
while two of the compounds are structurally similar to com-
pounds that have been shown to inhibit tau aggregation, the
third is quite different structurally and thus is the foundingmem-
ber of a new class of tau aggregation inhibitors. Interestingly, this
compound is the precursor to the azaphilone chemical class of
molecules, a class that includes compounds with lipoxygenase
inhibitor activity [28], another activity of potential value in the
treatment of dementia.Results
!
Because many A. nidulans secondary metabolites have chemical
structures similar to previously identified inhibitors of tau aggre-
gation, we sought to determinewhether these compoundswould
have biological activity in inhibiting tau aggregation in vitro. We
chose 17 compounds based on their preponderance of ring struc-
tures. These compounds include 8 anthraquinones, 5 xanthones,
and 4 other types of metabolites (l" Fig. 1). One compound (emo-
din) had been identified in an earlier study as an inhibitor of tau
aggregation [16]. Tau polymerization was initiated in vitro using
a standard arachidonic acid induction assay [35]. Each of the
compounds, at a concentration of 200 µM, was preincubatedwith
2 µM tau for 20min before the addition of 75 µM arachidonic ac-
Fig. 2 Filter trap assay of tau filament formation.
Tau polymerization reactions were performed with
2 µM tau and 75 µM arachidonic acid either with or
without 200 µM compound. The compounds used
are listed on the Y-axis. The resulting amount of tau
filament formation was determined by a filter trap
assay. The values for tau filament formation were
normalized to the amount of the no compound
control (dashed line). Negative values indicate that
there was less detectable tau on the filter after
treatment with a compound than was observed
with monomeric tau in the absence of arachidonic
acid. Values are the average of three trials ± SD.































































l.id. The amount of tau polymerization was determined using a fil-
ter trap assay [16,36].
Variecoxanthone, 2,ω-dihydroxyemodin, endocrocin, sterigma-
tocystin, asperthecin, chrysophanol, shamixanthone, and asper-
benzaldehyde reduced the amount of tau aggregation (l" Fig. 2).
Asperbenzaldehyde, asperthecin, and 2,ω-dihydroxyemodin had
the highest levels of inhibition. Although emodin inhibits tau ag-
gregation when the glycosaminoglycan heparin is used as an in-
ducer [16], it did not show appreciable inhibition in our assay. We
have previously shown that arachidonic acid is a more potent in-
ducer of tau aggregation than heparin [35], and we believe it is
likely that arachidonic acid, coupled with the particular tau iso-
formwe used, overwhelms the ability of emodin to inhibit tau ag-
gregation (see Discussion).
We then sought to confirm the inhibition of tau aggregation us-
ing electron microscopy, another technique used to quantify tau
aggregation reactions [40]. Asperthecin, asperbenzaldehyde,
sterigmatocystin, and 2,ω-dihydroxyemodin seemed to cause
the largest reduction in tau aggregation in comparison with con-
trol reactions without a compound (l" Fig. 3). We performed
quantitative analysis of the filament lengths in the presence and
absence of compounds. Filament lengths were placed into 50 nm
bins. The first bin is 30–50 nm because it is difficult to distinguish
tau particles below 30 nm in length from the background of the
electron microscope grid. All filaments above 200 nm in length
were binned together because this cutoff should represent par-
ticles retained by the filter trap assay. Inhibition reactions con-
taining the positive control emodin, emericellin, variecoxan-
thone, 2,ω-dihydroxyemodin, endocrocin, sterigmatocystin,
F9775A, F9775B, asperthecin, aloe emodin, demethylsterigmato-
cystin, ω-hydroxyemodin, monodictyphenone, 3′-hydroxyversi-
conol, and asperbenzaldehyde had filament length distributions
that were distinct from reactions without a compound (l" Fig. 4).
These differences tended to include more objects in the 30–
50 nm and 50–100 nm bins and fewer filaments in the > 200 nm
bin. Asperbenzaldehyde had the greatest effect on filament for-
mation with no filaments detected above 100 nm in length.
Many of the compounds reduced tau aggregation as measured by
either the filter trap assay or quantitative electron microscopy,supporting our rationale for choosing this set of compounds. Also,
four compounds showed a reduction in tau aggregation with
both the filter trap assay and electron microscopy: 2,ω-dihy-
droxyemodin, sterigmatocystin, asperthecin, and asperbenzalde-
hyde. We therefore sought to determine the IC50 for each com-
pound. The IC50 for sterigmatocystin could not be determined be-
cause it did not demonstrate a consistent and reproducible con-
centration-dependent decrease in tau filament formation (data
not shown). 2,ω-Dihydroxyemodin, asperthecin, and asperben-
zaldehyde gave reasonably consistent and reproducible concen-
tration-dependent decreases in tau filament formation and had
IC50 values of 205 ± 28 µM, 39 ± 2 µM, and 177 ± 103 µM, respec-
tively (l" Fig. 5).
We also determined whether these three compounds would in-
terfere with tauʼs normal function of stabilizing microtubules.
Microtubule polymerization was monitored using DAPI fluores-
cence in the presence of tau with and without a compound
(l" Fig. 6). Although 2,ω-dihydroxyemodin, asperthecin, and as-
perbenzaldehyde showed a dose-dependent reduction in tauʼs
stabilization of microtubules, significant tubulin stabilization re-
mained even at higher concentrations of inhibitors.Discussion
!
Tau filament formation is associated with many neurodegenera-
tive diseases and is likely a significant contributor to the accom-
panying neuronal dysfunction and death. There are currently no
available treatments to inhibit tau aggregation in Alzheimerʼs
disease or other related dementias. There is great interest in
identifying small molecules that may inhibit or reverse tau ag-
gregation. Previous studies have identified several classes of
compounds that show promise as aggregation inhibitors includ-
ing anthraquinones, phenothiazines, and a benzothiazolidine de-
rivative [13,14,16]. Many of the previously identified aggrega-
tion inhibitors share the common feature of containing aromatic
ring structures. It is believed that these ring structures could in-
teract with the β-structure that characterizes aggregation prone
tau conformations thereby preventing the propagation of fila-Paranjape SR et al. Inhibition of Tau… Planta Med 2014; 80: 77–85
Fig. 3 EM images of polymerization reactions. Tau
polymerization reactions were performedwith 2 µM
tau and 75 µM arachidonic acid either with or with-
out 200 µM compound. Aliquots of the reactions
were prepared for negative stain electron micros-
































































l.ment formation. While these compounds show promise, there
remains a need for additional lead compounds for further devel-
opment into potential therapeutics.
Many fungal natural products, including low molecular weight
secondary metabolites, have been shown to have pharmacologi-
cal properties such as acting as antibiotics, cholesterol synthesis
inhibitors, immunosuppressants, and others [41]. Recent advan-
ces in genetic manipulation of silent secondary metabolite syn-
thesis gene clusters have enhanced our capabilities to produce,
purify and characterize fungal natural products and also allow
the testing of these small molecules for biological or pharmaco-
logical activities. We have manipulated the genome of Aspergillus
nidulans to produce a wide variety of natural products in
amounts that allow ready purification [22,42]. Many of these
small compounds have aromatic ring structures similar to those
found in tau aggregation inhibitors.
2,ω-Dihydroxyemodin and asperthecin belong to the anthraqui-
none class of compounds. Other anthraquinones have previously
been shown to inhibit tau aggregation [16]. Notably, however, in
this study both of these compounds proved to be more potent in-
hibitors of tau polymerization than emodin, which has been pre-
viously shown to be a strong inhibitor with an IC50 in the range of
1–5 µM [16]. Although our compounds weremuchmore effective
at inhibiting tau aggregation than emodin, it was surprising thatParanjape SR et al. Inhibition of Tau… Planta Med 2014; 80: 77–85their IC50 values, in the range of 40–200 µM, were much higher
than those published for emodin. One likely explanation is that
our assay conditions strongly drive aggregation and provide a
particularly rigorous test for inhibition. The previous study was
done using the glycosaminoglycan heparin sulfate as an inducer
[16], and previous studies have shown that arachidonic acid in-
duces approximately three times the amount of aggregation as
heparin sulfate under similar conditions [35]. The previous emo-
din study also used 0N3R and 0N4R isoforms of tau [16], while
our current study uses 2N4R tau. Our previous studies show that
in the presence of arachidonic acid, 2N4R tau is muchmore prone
to aggregation than the 0N3R and 0N4R isoforms [43]. These fac-
tors together could account for the differences in IC50 values and
provide an explanation for why the IC50 values for our com-
pounds are much higher than those previously reported even
though they are more potent than emodin and, by inference, oth-
er previously reported tau aggregation inhibitors.
In our analysis, 2 of the 8 anthraquinones were active in blocking
tau aggregation while none of the xanthone compounds were as
effective. This could indicate the importance of the chemistry of
the central ring. Anthraquinones contain 2 keto groups on their
central ring, while xanthones contain a single keto group and an
ether linkage. It is possible that the keto groups in the central ring
are better aligned to interact with the beta-strand forming re-
Fig. 4 Filament length distributions. Filament lengths from electron micro-
graphs of tau polymerization reactions were measured, placed into 50 nm
bins (30–50 nm, 50–100 nm, 100–150 nm, 150–200 nm and > 200 nm), and
the lengths were summed to determine the total amount of filament length
in each bin. The first graph shows the control reaction without a compound,
and graphs (1)-(17) with the different compounds, being labeled with the
compound name and number. The filament distribution for the no-com-
pound control is redrawn on each graph as a light gray line for comparison.
Each point is the average distribution for images of at least 9 different
fields ± SD. * P ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001.
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Fig. 5 IC50 determina-
tion. Polymerization re-
actions at 2 µM tau and
75 µM arachidonic acid
were performed at sev-
eral different concen-
trations of the com-
pounds, and the result-
ing amount of filament
formation was deter-
mined by a filter trap






against the log of the
inhibitor concentration
and fit to a dose-re-
sponse curve (solid line)




hyde. Data points are
the average of three
trials ± SD.
Fig. 6 Microtubule as-
sembly. Tubulin was in-
cubated with either tau
protein alone (•) or tau
in the presence of
A 2,ω-dihydroxyemo-
din, B asperthecin, or
C asperbenzaldehyde
at compound concen-
trations of 50 µM (&)




over time (x-axis) and
normalized to microtu-
bule polymerization in
the presence of pacli-
taxel. Every third time
point is shown. Each
point is the average of
three independent tri-
als ± SD. The data are fit
to a Gompertz growth
curve (solid, dashed,
and dotted lines for no
compound, 50 µM and
100 µM compound, re-
spectively). * P ≤ 0.05;
































































l.gions of tau than the xanthone ring. It is interesting that the com-
pounds contain ring structures when considering that heparin
sulfate also contains ring structures and arachidonic acid can
adopt conformations in solution that could also be considered to
be ring-like in shape. It is possible that the inhibitory compounds
bind to tau in a manner similar to that of the inducers but block
the addition of more molecules of tau.
Asperbenzaldehyde has a single aromatic ring and is a stable in-
termediate in the asperfuranone biosynthetic pathway. It is par-
ticularly interesting because, as an azaphilone intermediate, it is
the founding member of a new class of compounds that inhibit
tau aggregation. Azaphilones are a particularly interesting group
of compounds because they exhibit a great variety of biologically
important activities including antioxidant and anti-inflamma-
tory activities (reviewed in [44]). Another interesting property
of asperbenzaldehyde is that, while it has weak lipoxygenase-1
(LOX-1) inhibitory activity, simple modifications convert it into
a series of strong LOX-1 inhibitors [28]. Inhibition of LOX-1 may
help to reduce fatty acid metabolites of arachidonic acid and do-Paranjape SR et al. Inhibition of Tau… Planta Med 2014; 80: 77–85cosahexanoic acid that are elevated in Alzheimerʼs disease [45],
and it is possible that derivatives of asperbenzaldehyde may have
more than one positive therapeutic activity in tau dementias.
One goal of tau therapeutics is that they should prevent undesir-
able tau aggregation while still retaining normal tau function of
stabilizing the assembly of tubulin intomicrotubules. These com-
pounds do reduce tau function but do not completely inhibit it. It
is perhaps not surprising that some diminution occurs in the
presence of compounds because the sequences likely responsible
for tau aggregation are 275VQIINK280 and 306VQIVYK311 which re-
side in the microtubule binding repeats [10,11]. If the com-
pounds are interacting with these sequences as a mechanism for
inhibiting tau aggregation, they would also likely have some im-
pact on microtubule stabilization. It is encouraging that these
compounds do allow some retention of tau function and thus
are promising as future seed compounds to obtain derivatives
with even greater ability to inhibit tau aggregationwith fewer ef-
fects on tauʼs normal function of stabilizing microtubules.
83Original PapersIn conclusion, this report shows that selected secondary metabo-
lites from fungi include seed compounds that may be modified
for further therapeutic benefit. We have also provided another
example of the wide application of fungal natural products.
Lastly, we have identified an azaphilone precursor, asperbenzal-
dehyde, that inhibits both tau aggregation and LOX-1. The fact
that asperbenzaldehyde has a quite different chemical structure
from previously identified small molecule inhibitors of tau ag-
































































Full length 2N4R tau (441 amino acids) was expressed in E. coli
and purified as described previously [46]. Arachidonic acid
(ARA) was purchased from Cayman Chemicals. Compounds were
purified from Aspergillus nidulans as described previously [28,29,
31,32,47,48] from a single peak of HPLC chromatography, and
purity was estimated by NMR (see Table 1S and Fig. 1S, Support-
ing Information).
ARA-induced tau polymerization reactions
2 µM recombinant tau protein was incubated in polymerization
buffer which contained 10mM HEPES (pH 7.64), 5mM DTT,
100mM NaCl, 0.1mM EDTA, and 3.75% ethanol. Compounds dis-
solved in DMSO were added to the tau solution at final concen-
trations of 200 µM, 100 µM, 50 µM, or 25 µM as described in Re-
sults. Compounds were allowed to incubate with tau for 20min
before the addition of 75 µM arachidonic acid to initiate tau fila-
ment formation [35]. The reactions were allowed to proceed at
room temperature for 16 h before analysis.
Filter trap assay
Tau polymerization reactions, as described above, were diluted to
20 ng/300 µL in TBS and passed through a pre-wetted nitrocellu-
lose membrane (Bio-Rad Laboratories) using vacuum force in a
dot-blot apparatus (Bio-Rad Laboratories). The membranes were
washed thrice with TBS-0.05% Tween20 (TBST) and then blocked
in 5% nonfat dry milk in TBST for 1 h. The membranes were then
incubatedwith primary antibodymixture [Tau 5 [49] at 1 :50000
dilution, Tau 12 [50] at 1:250000 dilution, and Tau 7 [51] at
1:250000 dilution; antibodies were a kind gift from Dr. Lester I.
Binder] overnight at 4°C. Membranes werewashed thrice in TBST
and incubated with secondary antibody, HRP-linked goat anti-
mouse IgG (Thermo Scientific), for 1 h at room temperature. The
membranes were washed twice in TBS-Tween buffer, and a final
wash was made with TBS. The blot was developed using an ECL
(enhanced chemiluminescence) Western blotting analysis sys-
tem (GE Healthcare). Images were captured with a Kodak Image
Station 4000R and were quantified using the histogram function
of Adobe Photoshop 7.0. Statistical analyses were performed us-
ing 1-way ANOVA with Dunnettʼs multiple comparison test to
compare the triplicate values to control values.
Transmission electron microscopy
Polymerization reaction samples were diluted 1:10 in
polymerization buffer and fixed with 2% glutaraldehyde for
5min. 10 µL of each sample was added to a Formvar carbon-
coated grid for 1min. The grid was blotted on filter paper,
washed with water, blotted, washed with 2% uranyl acetate and
blotted before staining with 2% uranyl acetate for 1min followedby a final blotting on filter paper. The grids were examinedwith a
Technai F20 XT field emission transmission electron microscope
(FEI Co.). Images were taken with the Gatan Digital Micrograph
imaging system. The images were collected at a magnification of
3600×. The filaments were quantified using Image-Pro Plus 6.0
software [35]. The perimeter of the filaments was determined,
and the length was obtained by dividing the perimeter in half.
For quantitative analysis, filament lengths were placed into bins
as described in Results. Statistical analyses were performed using
two-way ANOVAwith Bonferroni post-tests to compare replicate
means for each bin size with the no compound data serving as
reference values.
Tubulin polymerization assay
Polymerization of tubulin was measured using a tubulin
polymerization assay kit (Cytoskeleton, Inc.). The reactions were
measured in 96-well Costar black polystyrene flat-bottom plates
(Corning, Inc.). Each well contained porcine tubulin at 2mg/mL
and GTP at 1mM in 80mM PIPES buffer (pH 6.9) with 2mM
MgCl2 and 0.5mM EGTA. Tau was added to the wells at a concen-
tration of 1 µM, and the test compounds diluted in DMSO were
added at a final concentration of 200 µM. An equal amount of
DMSO was added to each of the wells. Another well containing
1 µM paclitaxel (99.1% pure; Cytoskeleton, Inc.) and tubulin
served as a positive control for polymerization and as a standard
for normalizing results for each of the experiments (not shown).
Control reactions containing only buffer without either tau or a
compound, and buffer with the individual test compounds but
without tau were also performed (not shown). Reaction plates
were placed at 37°C and shaken for 5 s in a FlexStation II fluo-
rometer (Molecular Devices Corp.). The fluorescence was mea-
sured at a constant interval of 1 minute for an hour with an exci-
tation wavelength (λex) of 355 nm and an emission wavelength
(λem) of 455 nm. This gave 60 readings for every well sample.
The resulting data were normalized to the amount of microtu-
bule polymerization observed in the presence of tau without a
compound and fit to the Gompertz equation [43]. Experiments
were performed in triplicate and averaged. Statistical analyses
and individual growth parameters can be found in Table 2S, Sup-
porting Information.
Supporting information
Data on the estimated purity of the tested compounds based on
1H NMR spectra and the spectrum of emericellin used to deter-
mine compound purity are available as Supporting Information.Acknowledgements
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